Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients

Transplant Infectious Disease

Volumn 18, Issue 4, 2016, Pages 628-633

  Webb, B J ^a   Brunner, A ^b   Ford, C D ^b   Gazdik, M A ^a   Petersen, F B ^b   Hoda, D ^b  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b LDS HOSPITAL   (United States)

Author keywords

Clostridium difficile infection; fecal microbiota transplantation; graft versus host disease; hematopoietic stem cell transplantation; microbiome

Indexed keywords

CEPHALOSPORIN; FIDAXOMICIN; NITAZOXANIDE; RIFAXIMIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL OVERGROWTH; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DONOR SELECTION; DRUG MEGADOSE; FECAL MICROBIOTA TRANSPLANTATION; FECES CULTURE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; UPPER RESPIRATORY TRACT INFECTION;

EID: 84981164544     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12550     Document Type: Article

References (21)

1. Callejas-Diaz A, Gea-Banacloche JC. Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation. Curr Hematol Malig Rep 2014; 9 (1): 85–90.
2. Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis 2012; 14 (6): E161–E165.
3. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108 (4): 500–508.
4. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109 (7): 1065–1071.
5. de Castro CG Jr, Ganc AJ, Ganc RL, Petrolli MS, Hamerschlack N. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. Bone Marrow Transplant 2015; 50 (1): 145.
6. US Food and Drug Administration. Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. Rockville, MD: U.S. Department of Health and Human Services, 2013.
7. Herfarth HH, Long MD, Rubinas TC, Sandridge M, Miller MB. Evaluation of a non-invasive method to detect cytomegalovirus (CMV)-DNA in stool samples of patients with inflammatory bowel disease (IBD): a pilot study. Digest Dis Sci 2010; 55 (4): 1053–1058.
8. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107 (5): 761–767.
9. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368 (5): 407–415.
10. National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events, Version 3.0. Rockville, MD: US Department of Health and Human Services, 2006.
11. Aroniadis OC, Brandt LJ. Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterol Hepatol 2014; 10 (4): 230–237.
12. Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20 (5): 640–645.
13. Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124 (7): 1174–1182.
14. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54 (8): 1053–1063.
15. Huang H, Wu S, Chen R, et al. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. Anaerobe 2014; 30C: 65–69.
16. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58 (11): 1515–1522.
17. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107 (7): 1079–1087.
18. Rezvani AR, Storb RF. Prevention of graft-vs.-host disease. Expert Opin Pharmacother 2012; 13 (12): 1737–1750.
19. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med 2013; 2 (1): 25–32.
20. Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol 2010; 22 (4): 455–460.
21. Murphy S, Nguyen VH. Role of gut microbiota in graft-versus-host disease. Leukemia Lymphoma 2011; 52 (10): 1844–1856.